<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03421678</url>
  </required_header>
  <id_info>
    <org_study_id>2017NTLS019</org_study_id>
    <nct_id>NCT03421678</nct_id>
  </id_info>
  <brief_title>Ethnic/Racial Differences in Metabolism and DNA Adduct Formation</brief_title>
  <official_title>Ethnic/Racial Differences in Metabolism and DNA Adduct Formation by 1,3-butadiene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate the role of 1,3-butadiene metabolic activation and deactivation in&#xD;
      lung cancer risk among various ethnic/racial groups. This project will require urine samples&#xD;
      from smokers and nonsmokers from the three ethnic/racial groups recruited by the Clinical and&#xD;
      Biomarker Core for the analysis of 1,3-butadiene DNA adducts. Data on nicotine intake&#xD;
      (urinary TNE) in these subjects as well as in 400 lung cancer cases and 400 controls from&#xD;
      Project 1 will be also required for this project.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was completed at other sites&#xD;
  </why_stopped>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Butadiene-DNA adducts in different ethnic groups</measure>
    <time_frame>Day 1 &amp; 2</time_frame>
    <description>Investigate ethnic differences in butadiene-DNA adducts in smokers belonging to different ethnic groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Butadiene-DNA adduct load in smokers with lung cancer</measure>
    <time_frame>Day 1 &amp; 2</time_frame>
    <description>Investigate the association between butadiene-DNA adduct load and lung cancer development in smokers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Polymorphisms of carnicogen metabolizing genes</measure>
    <time_frame>Day 1 &amp; 2</time_frame>
    <description>Examine how polymorphisms of carcinogen metabolizing genes influence metabolic inactivation, DNA adduct formation/repair, and toxicity of butadiene-derived epoxides.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Japanese American</arm_group_label>
    <description>Two parents of Japanese descent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Hispanic Whites</arm_group_label>
    <description>Two parents of non-Hispanic white descent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Native Hawaiians</arm_group_label>
    <description>At least one parent of Hawaiian descent</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Urine Sample</intervention_name>
    <description>One to two home visits where tobacco use and medical history and biological samples will be collected including blood, buccal cells and urine</description>
    <arm_group_label>Japanese American</arm_group_label>
    <arm_group_label>Native Hawaiians</arm_group_label>
    <arm_group_label>Non-Hispanic Whites</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Approximately 300 smokers will be recruited from the Multiethnic Cohort (MEC) study or the&#xD;
        general population in Hawai'i&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  One of the three targeted ethnic groups:&#xD;
&#xD;
               -  Japanese American - two parents of Japanese descent&#xD;
&#xD;
               -  Non-Hispanic Whites - two parents of non-Hispanic white descent&#xD;
&#xD;
               -  Native Hawaiians will include individuals with at least one parent of Hawaiian&#xD;
                  descent;&#xD;
&#xD;
          -  Smoke 5 cigarettes per day over the past three months;&#xD;
&#xD;
          -  &gt;21 years of age;&#xD;
&#xD;
          -  Consumes 14 or fewer drinks of alcohol per week;&#xD;
&#xD;
          -  Generally stable and good health (determined by review of medical history);&#xD;
&#xD;
          -  Able to provide written voluntary consent before performance of any study related&#xD;
             procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current use of other nicotine containing products for &gt; 4 times per month (and no use&#xD;
             of any nicotine-containing products except cigarettes for 2 weeks prior to their study&#xD;
             visits);&#xD;
&#xD;
          -  Acute or uncontrolled medical or psychiatric conditions;&#xD;
&#xD;
          -  Currently taking any medications that affect relevant metabolic enzymes or anti-&#xD;
             inflammatory medications such as ibuprofen (this will be reviewed by study&#xD;
             investigators on a case-by-case basis);&#xD;
&#xD;
          -  Active infection (e.g., influenza, cold, respiratory infection, sinus infection) at&#xD;
             the time of the visit;&#xD;
&#xD;
          -  Pregnant or nursing or planning on becoming pregnant during the study;&#xD;
&#xD;
          -  Unable to read and understand English.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorothy Hatsukami, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota, Department of Psychiatry</affiliation>
  </overall_official>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

